Citigroup Cuts Bruker (NASDAQ:BRKR) Price Target to $53.00

Bruker (NASDAQ:BRKR) had its price target dropped by analysts at Citigroup from $60.00 to $53.00 in a report issued on Wednesday,Benzinga reports. The firm currently has a “neutral” rating on the medical research company’s stock. Citigroup’s price objective suggests a potential upside of 0.83% from the stock’s previous close.

Several other research analysts have also issued reports on BRKR. Weiss Ratings upgraded shares of Bruker from a “sell (d)” rating to a “sell (d+)” rating in a research report on Wednesday, June 3rd. Leerink Partners increased their price objective on Bruker from $60.00 to $70.00 and gave the company an “outperform” rating in a research report on Tuesday, July 7th. Wall Street Zen raised Bruker from a “hold” rating to a “buy” rating in a report on Saturday, May 9th. TD Cowen reiterated a “hold” rating on shares of Bruker in a research report on Wednesday, July 15th. Finally, Barclays lifted their price target on Bruker from $53.00 to $60.00 and gave the stock an “overweight” rating in a research note on Wednesday, June 24th. One analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating, five have given a Hold rating and two have assigned a Sell rating to the company. According to data from MarketBeat.com, the company has a consensus rating of “Hold” and a consensus target price of $56.64.

Bruker Price Performance

Bruker stock traded up $2.26 during midday trading on Wednesday, hitting $52.56. The company’s stock had a trading volume of 3,019,318 shares, compared to its average volume of 2,417,919. Bruker has a 12 month low of $28.53 and a 12 month high of $65.30. The company has a quick ratio of 0.72, a current ratio of 1.55 and a debt-to-equity ratio of 0.67. The company has a market capitalization of $8.00 billion, a PE ratio of -218.21, a price-to-earnings-growth ratio of 2.06 and a beta of 1.28. The stock’s 50-day moving average price is $58.59 and its 200-day moving average price is $46.71.

Bruker (NASDAQ:BRKR) last announced its quarterly earnings data on Tuesday, August 4th. The medical research company reported $0.49 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.38 by $0.11. Bruker had a negative net margin of 0.65% and a positive return on equity of 11.60%. The company had revenue of $838.50 million for the quarter, compared to analysts’ expectations of $853.57 million. During the same quarter in the previous year, the company posted $0.32 EPS. The business’s revenue was up 5.2% compared to the same quarter last year. Bruker has set its FY 2026 guidance at 2.100-2.150 EPS. Analysts anticipate that Bruker will post 2.12 earnings per share for the current fiscal year.

Institutional Trading of Bruker

Several institutional investors have recently made changes to their positions in the stock. Orbis Allan Gray Ltd purchased a new position in Bruker during the second quarter valued at approximately $192,735,000. Price T Rowe Associates Inc. MD lifted its position in Bruker by 2,963.4% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 2,366,520 shares of the medical research company’s stock worth $111,488,000 after buying an additional 2,289,269 shares in the last quarter. AQR Capital Management LLC boosted its stake in shares of Bruker by 125.3% during the 2nd quarter. AQR Capital Management LLC now owns 3,326,820 shares of the medical research company’s stock valued at $137,065,000 after buying an additional 1,850,215 shares during the period. Franklin Resources Inc. boosted its stake in shares of Bruker by 317.7% during the 4th quarter. Franklin Resources Inc. now owns 2,309,404 shares of the medical research company’s stock valued at $108,796,000 after buying an additional 1,756,460 shares during the period. Finally, Millennium Management LLC grew its holdings in shares of Bruker by 222.6% during the 4th quarter. Millennium Management LLC now owns 1,839,587 shares of the medical research company’s stock valued at $86,663,000 after acquiring an additional 1,269,316 shares in the last quarter. 79.52% of the stock is currently owned by institutional investors and hedge funds.

Trending Headlines about Bruker

Here are the key news stories impacting Bruker this week:

• Positive Sentiment: Bruker reported second-quarter adjusted earnings of $0.49 per share, well above the $0.38 analyst consensus and up from $0.32 a year earlier. The earnings beat and stronger margins provide support for the stock. Bruker Q2 Earnings Beat Estimates
• Positive Sentiment: Management maintained fiscal 2026 adjusted EPS guidance of $2.10 to $2.15, broadly in line with the $2.12 consensus. The earnings outlook was not reduced despite the revenue guidance adjustment. Bruker Corporation Earnings Call Highlights Margin Strength
• Neutral Sentiment: Second-quarter revenue increased 5.2% year over year to $838.5 million, but missed the $853.6 million analyst estimate. The mixed result helps explain investor caution even as earnings exceeded expectations. Bruker Q2 Earnings Snapshot
• Negative Sentiment: Bruker lowered its fiscal 2026 reported revenue guidance to approximately $3.54 billion-$3.57 billion from $3.57 billion-$3.60 billion. Management attributed the change primarily to foreign exchange and tax assumptions, but investors remain focused on slower growth in the company’s core markets. Weak Growth in Its Primary Market Continues to Weigh Heavily on Bruker Shares
• Negative Sentiment: About $20 million of revenue is expected to shift from the third quarter into the fourth quarter because of semiconductor-customer delivery timing, creating a weaker near-term revenue profile. Bruker also recorded a $134.9 million non-cash goodwill impairment, resulting in a GAAP loss for the quarter. Bruker Revenue Outlook and Q3 Timing Shift

Bruker Company Profile

Bruker Corporation, founded in 1960 by physicist Günther Laukien and headquartered in Billerica, Massachusetts, is a leading developer and manufacturer of high-performance scientific instruments and analytical solutions. The company designs systems that enable molecular and materials research across academic, governmental, and industrial laboratories.

Bruker’s product portfolio encompasses nuclear magnetic resonance (NMR) spectrometers for molecular structure and dynamics studies, mass spectrometry platforms for proteomics and metabolomics, X-ray diffraction and scattering instruments for crystallography and materials characterization, atomic force and scanning probe microscopes for nanoscale surface analysis, as well as preclinical imaging systems such as micro-CT and MRI scanners.

In addition to hardware, Bruker provides software suites, applications support, training services, and long-term maintenance agreements to ensure optimal instrument performance.